| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.61 mm | 2.61 mm | 2.61 mm | 2.61 mm | 2.61 mm | 2.61 mm |
| Cash burn (monthly) | 593.57 k | 593.27 k | 1.19 mm | 1.56 mm | 659.86 k | 1.05 mm |
| Cash used (since last report) | 2.81 mm | 2.81 mm | 5.65 mm | 7.37 mm | 3.12 mm | 4.96 mm |
| Cash remaining | -201.83 k | -200.44 k | -3.04 mm | -4.77 mm | -515.47 k | -2.36 mm |
| Runway (months of cash) | -0.3 | -0.3 | -2.5 | -3.1 | -0.8 | -2.2 |
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 3 |
| Closed positions | 6 |
| Increased positions | 3 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 769.73 mm |
| Total shares | 3.47 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Lung Therapeutics | 2.95 mm | $42.24 mm |
| Armistice Capital | 228.00 k | $458.28 mm |
| Intracoastal Capital | 155.59 k | $428.00 k |
| DRW Securities | 40.00 k | $80.40 mm |
| Geode Capital Management | 28.00 k | $56.28 mm |
| Renaissance Technologies | 20.50 k | $41.20 mm |
| Vanguard | 12.14 k | $24.39 mm |
| Nwam | 10.24 k | $20.58 mm |
| Wealthgarden F.S. | 10.24 k | $20.58 mm |
| BlackRock | 7.19 k | $14.44 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jul 24 | Zamaneh Mikhak | Common Stock | Grant | Acquire A | No | No | 0 | 10,184 | 0.00 | 145,184 |
| 3 Jul 24 | Zamaneh Mikhak | Stock Options Common stock | Grant | Acquire A | No | No | 1.82 | 10,184 | 18.53 k | 10,184 |
| 3 Jul 24 | Kirk Allen Coleman | Common Stock | Grant | Acquire A | No | No | 0 | 10,184 | 0.00 | 45,859 |
| 3 Jul 24 | Kirk Allen Coleman | Stock Options Common Stock | Grant | Acquire A | No | No | 1.82 | 10,184 | 18.53 k | 10,184 |
| 3 Jul 24 | Stephen Rocamboli | Common Stock | Grant | Acquire A | No | No | 0 | 3,165 | 0.00 | 39,165 |
| 3 Jul 24 | Stephen Rocamboli | Stock Options Common stock | Grant | Acquire A | No | No | 1.82 | 3,165 | 5.76 k | 3,165 |
| 3 Jul 24 | Roberts Brandi | Common Stock | Grant | Acquire A | No | No | 0 | 3,165 | 0.00 | 23,165 |
| 3 Jul 24 | Roberts Brandi | Stock Options Common stock | Grant | Acquire A | No | No | 1.82 | 3,165 | 5.76 k | 3,165 |
| 3 Jul 24 | Robert S Mills | Common Stock | Grant | Acquire A | No | No | 0 | 3,165 | 0.00 | 59,145 |
| 3 Jul 24 | Robert S Mills | Stock Options Common stock | Grant | Acquire A | No | No | 1.82 | 3,165 | 5.76 k | 3,165 |
